Billions in pharma tax savings went to investors, not R&D: Oxfam by Kyle Blankenship Monday, April 15, 2019 J&J, Merck, Pfizer and Abbott reaped a combined $7 billion in savings from two tax reform provisions, and they spent most of it on investor payouts.
AbbVie caps its post-tax break giving with $40M to local school by Beth Snyder Bulik Monday, March 25, 2019 AbbVie capped the donations drawn from its 2018 tax break gains by pledging $40 million to rebuild a middle school near its headquarters.
Drugmakers shifting profits to dodge billions in taxes: report by Eric Sagonowsky Thursday, September 20, 2018 Pharma companies Pfizer, Merck and Johnson & Johnson are dodging billions of dollars of tax payments annually, an Oxfam report concluded.
AbbVie's tax rate cut—biggest in pharma—yields $100M donation by Beth Snyder Bulik Wednesday, August 22, 2018 AbbVie donated $100 million to Ronald McDonald House Charities this week, part of its ongoing 2018 tax-windfall handout of $350 million to charities.
AbbVie Humira patents in Bermuda enable big tax savings: Reuters by Eric Sagonowsky Wednesday, June 20, 2018 AbbVie has stored dozens of Humira patents in Bermuda, allowing it to lower its corporate tax rate, according to Reuters.
Industry veteran Jeremy Levin calls out pharma's buybacks by Eric Sagonowsky Wednesday, June 6, 2018 Pharma authorized tens of billions of dollars' worth of share buybacks before or shortly after tax reform, and that irked an industry veteran.
9. AbbVie by Eric Sagonowsky AbbVie had a monster year in 2017, leading the industry in stock price performance as its megadrug Humira proved unstoppable.
Will tax-boosted Big Pharma beat Takeda to a Shire deal? by Carly Helfand Friday, March 30, 2018 Takeda hasn’t even approached Shire’s board with a buyout offer yet, but competing bidders could jump in quickly, thanks to U.K. takeover rules.
Pfizer hands CEO massive pay raise plus $8M share bonus by Arlene Weintraub Friday, March 16, 2018 Pfizer’s board of directors is providing rich incentives to keep CEO Ian Read on board as the company navigates a host of challenges.
